The Priority Review

Clinical trials Brief

Genmab posts results of Phase 3 epcoritamab trial in relapsed/refractory DLBCL

Results for the EPCORE DLBCL-1 study were first posted on ClinicalTrials.gov on November 3, 2026. The randomized, open-label Phase 3 trial enrolled 483 participants and compared subcutaneous epcoritamab with investigator's choice chemotherapy (R-GemOx or BR) in relapsed/refractory diffuse large B-cell lymphoma.

Primary source

ClinicalTrials.gov results record, November 3, 2026

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Read the source clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation